Luis M Ruilope, MD looks at the evidence showing that currently available therapies leave room for improvement in the reduction of CV events in patients with diabetes and chronic kidney disease.
- To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
- To understand the origin of the high residual cardiovascular risk in patients with diabetes and kidney disease
- To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD and CKD
- To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management
- Luis M Ruilope, MD , Hospital 12 de Octubre Madrid, Spain
The symposium was supported by an unrestricted educational grant from Resverlogix CorpThe information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?Molecular mechanisms involved in the beneficial effect of BET inhibition in experimental renal disease
- Managing CKD, Diabetes & CVD: Is epigenetics a new way forward?BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?
Kamyar Kalantar-Zade, MD